T. Rowe Price Associates
TEVA icon

T. Rowe Price Associates’s Teva Pharmaceuticals TEVA Stock Holding History

T. Rowe Price Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,700
Closed -$350K – 2564
2018
Q4 		$350K Hold
22,700
– – ﹤0.01% 2222
2018
Q3 		$489K Hold
22,700
– – ﹤0.01% 2160
2018
Q2 		$552K Hold
22,700
– – ﹤0.01% 2090
2018
Q1 		$388K Buy
+22,700
New +$443K ﹤0.01% 2183

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's TEVA Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Teva Pharmaceuticals (TEVA) stake by 59% in Q1 2026, selling an estimated $29.8M and leaving 634,136 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

T. Rowe Price Associates first reported a position in TEVA in Q2 2013 and has held it in 47 quarters since. The position peaked at $462M in Q1 2015. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • T. Rowe Price Associates held 634,136 shares of Teva Pharmaceuticals worth $19.1M as of Q1 2026.
  • T. Rowe Price Associates sold 925,466 Teva Pharmaceuticals shares in Q1 2026, an estimated $29.8M.
  • Teva Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1052 holding.
  • T. Rowe Price Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • T. Rowe Price Associates's Teva Pharmaceuticals position peaked at $462M in Q1 2015.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.